Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

BACKGROUND: The mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumours (PNETs). However, adaptive resistance to mTOR inhibition is described. METHODS: QGP-1 and BON-1, two human PNET cell lines, were cultured with increasing concentrations of evero...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandamme, Timon, Beyens, Matthias, de Beeck, Ken Op, Dogan, Fadime, van Koetsveld, Peter M, Pauwels, Patrick, Mortier, Geert, Vangestel, Christel, de Herder, Wouter, Van Camp, Guy, Peeters, Marc, Hofland, Leo J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800296/
https://www.ncbi.nlm.nih.gov/pubmed/26978006
http://dx.doi.org/10.1038/bjc.2016.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800296/
https://www.ncbi.nlm.nih.gov/pubmed/26978006
http://dx.doi.org/10.1038/bjc.2016.25

Ejemplares similares